Unibest

UB139

TargetsPCSK9 (siRNA)
IndicationsHypercholesterolaemia
ClinicalI
TherapeuticsMetabolic & Endocrinology
ModalitiesNucleic Acid Therapeutics

Exclusive Summary

  • Capitalize on patent cliffs or high technical barriers to secure First-to-Market or early-entry opportunities globally.
  • Target high-burden therapeutic areas aligned with first-line international guidelines, ensuring rigid and sustainable demand.
  • Leverage China’s vertically integrated supply chain to offer superior cost-efficiency compared to originators and global competitors.
  • The NewCo model facilitates deep localization, accelerating regulatory access and maximizing commercial value through shared risk/reward.

Asset Materials

UB139 Asset Materials

我们能如何帮助您?

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →